Understand how avidity can accelerate preclinical drug development by reading our latest white papers
Cell Avidity: a key to accelerate IND filing in cell therapy drug development
In this white paper, we discuss current challenges in the lengthy and iterative preclinical development pipeline for cell therapies and how cell avidity can improve confidence in lead candidate selection to speed up IND filings
Accelerating the preclinical development of Cell Engagers for cancer immunotherapy through Cell Avidity, a novel biomarker for improved antitumor efficacy
In this white paper, we discuss how cell engagers could overcome challenges presented by current CAR-T therapies and how the new LUMICKS high throughput service platform can measure hundreds of cell engagers for rapid and cost-effective selection of the most potent cell engagers.
